



**Australian Government**  
**Department of Health and Aged Care**  
Therapeutic Goods Administration

## Public Summary

<b>Summary for ARTG Entry:</b>	274997	METAGENICS INFLA-MOOD
<b>ARTG entry for</b>	Medicine Listed	
<b>Sponsor</b>	Metagenics (Aust) Pty Ltd	
<b>Postal Address</b>	PO Box 675, VIRGINIA BC, QLD, 4014 Australia	
<b>ARTG Start Date</b>	5/05/2016	
<b>Product Category</b>	Medicine	
<b>Status</b>	Active	
<b>Approval Area</b>	Listed Medicines	

### Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

### Products

#### 1 . METAGENICS INFLA-MOOD

<b>Product Type</b>	Single Medicine Product	<b>Effective Date</b>	6/05/2020
---------------------	-------------------------	-----------------------	-----------

#### Permitted Indications

Antioxidant/Reduce free radicals formed in the body  
Helps reduce/decrease free radical damage to body cells  
Maintain/support general health and wellbeing  
Anti-inflammatory/relieve inflammation  
Maintain/support healthy digestion  
Aid/assist/helps synthesis of neurotransmitters  
Maintain/support nervous system health  
Support healthy emotional/mood balance  
Traditionally used in Persian/Iranian medicine to support healthy emotional/mood balance

#### Indication Requirements

Product presentation must not imply or refer to mental illnesses, disorders or conditions.  
Label statement: If symptoms persist, talk to your health professional.

#### Standard Indications

No Standard Indications included on Record

#### Specific Indications

No Specific Indications included on Record

#### Warnings

If symptoms persist consult your healthcare practitioner (or words to that effect).

#### Additional Product information

Public Summary



**Australian Government**  
**Department of Health and Aged Care**  
Therapeutic Goods Administration

**Pack Size/Poison information**

**Pack Size**

**Poison Schedule**

**Components**

**1 . Formulation 1**

**Dosage Form** Capsule, hard

**Route of Administration** Oral

**Visual Identification**

**Active Ingredients**

<b>Crocus sativus stigma Extract dry concentrate</b>	<b>15 mg</b>
Equivalent: Crocus sativus (Dry)	45 mg
<b>Curcuma longa rhizome Extract dry concentrate</b>	<b>500 mg</b>
Equivalent: Curcuma longa (Dry)	12.5 g

**Other Ingredients (Excipients)**

chlorophyllin-copper complex  
disodium edetate  
gellan gum  
hypromellose  
magnesium stearate  
microcrystalline cellulose  
potassium acetate  
purified water  
sorbitan monolaurate

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary